


Comparison of structural magnetic resonance imaging findings between neuropsychiatric systemic lupus erythematosus and systemic lupus erythematosus patients: A systematic review and meta-analysis

Rheumatology Practice and Research
Volume 2: 1–11
© The Author(s) 2017
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/2059902116663058
rpr.sagepub.com


Omed Amin¹, Arvind Kaul², Toby O Smith³,
Franklyn A Howe⁴ and Nidhi Sofat¹

Abstract

Introduction: Neuropsychiatric systemic lupus erythematosus is often clinically challenging to diagnose, treat and monitor. Although brain magnetic resonance imaging is frequently performed before lumbar puncture in neuropsychiatric systemic lupus erythematosus, it is not clear from the literature whether specific brain magnetic resonance imaging findings are associated with distinct clinical features of neuropsychiatric systemic lupus erythematosus.

Methods: We conducted a systematic review and meta-analysis on published studies of neuropsychiatric systemic lupus erythematosus including brain magnetic resonance imaging and the 1999 American College of Rheumatology-defined clinical neuropsychiatric systemic lupus erythematosus syndromes to determine their relationship. Pooled prevalence and risk ratio for distinct neuropsychiatric systemic lupus erythematosus associations were determined with 95% confidence intervals.

Results: Of 821 studies screened, 21 fulfilled inclusion criteria. A total of 818 participants were evaluated (91% female) with 1064 neuropsychiatric systemic lupus erythematosus episodes assessed. Neuropsychiatric systemic lupus erythematosus features included headache (24%), seizures (19%), cerebrovascular disease (18%), cognitive dysfunction (15%) and acute confusional state (14%). Normal magnetic resonance imaging was significant for anxiety disorder (risk ratio: 9.00; 95% confidence interval: 2.40, 33.79), autonomic disorder (risk ratio: 7.00; 95% confidence interval: 0.51, 96.06) and plexopathy (risk ratio: 5.00; 95% confidence interval: 0.81, 31.00). Highest risk ratio of neuropsychiatric systemic lupus erythematosus syndrome with abnormal magnetic resonance imaging was observed for cerebrovascular disease (risk ratio: 0.15; 95% confidence interval: 0.10, 0.24) and demyelination (risk ratio: 0.11; 95% confidence interval: 0.02, 0.72).

Conclusion: Normal magnetic resonance imaging in neuropsychiatric systemic lupus erythematosus was the most significant correlate from our meta-analysis for psychological symptoms including anxiety and peripheral nerve features of autonomic disorder and plexopathy. The main abnormal brain magnetic resonance imaging correlates included cerebrovascular disease and demyelination. Brain magnetic resonance imaging correlates poorly with neuropsychiatric systemic lupus erythematosus features, and specific clinical symptoms should be the main determinants of performing magnetic resonance imaging rather than presence of neuropsychiatric systemic lupus erythematosus per se.

¹Institute for Infection and Immunity, St George's, University of London, London, UK

²Department of Rheumatology, St George's University Hospitals NHS Foundation Trust, London, UK

³Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK

⁴Institute of Cardiovascular and Cell Sciences, St George's, University of London, London, UK

Corresponding author:

Nidhi Sofat, Institute for Infection and Immunity, St George's, University of London, Cranmer Terrace, London SW17 0RE, UK.
Email: nsifat@sgul.ac.uk



Keywords

SLE, neuropsychiatric features, MRI, brain imaging

Date received: 11 December 2015; accepted: 1 June 2016

Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that affects multiple organ systems with inflammation, immune complex deposition and vasculopathy as the primary pathological findings. The disease prevalence of SLE varies worldwide from 13 to 51 cases per 100,000 and has been reported as increasing due to improvements in survival.^{1,2} The condition shows a marked female predominance, being approximately nine times as common in women than in men.^{3–5}

Neuropsychiatric systemic lupus erythematosus (NPSLE) is characterised by diverse syndromes affecting both the central and peripheral nervous systems (CNS and PNS). Features can range from mild headaches to more severe manifestations, such as epilepsy, cerebrovascular disease, psychiatric disorders, cranial and peripheral neuropathies.^{6,7} NPSLE features can be difficult to distinguish from other diseases, while the heterogeneity of the condition can make the conduct of research challenging. Objective and subjective criteria have been used for inclusion in studies, while variations in baseline patient characteristics and duration of observation may add to the inconsistency of the reported data.^{6,8,9} The prevalence of neuropsychiatric NPSLE varies from 31% to 91%.⁹

Several processes have been implicated in the pathogenesis of NPSLE. Local release of inflammatory cytokines, autoantibody-mediated response to CNS components and formation of immune complexes, resulting in cerebrovasculopathic changes and neuronal injury may all be key.^{10–13} The presence of antiphospholipid antibodies may exacerbate the disease, increasing the risk of thrombotic arterial or venous disease and accelerated atherosclerosis.¹⁴

Diagnosis and management options are dependent on the underlying syndrome. The adoption of cerebrospinal fluid (CSF) analysis, electroencephalography (EEG) and neuroimaging techniques has been recommended by the European League Against Rheumatism (EULAR) task force for the diagnosis of NPSLE or to exclude concomitant illnesses, infection or drug side effects.¹⁵ Despite this, correct attribution of neuropsychiatric events to NPSLE remains a clinical challenge as there is no gold standard diagnostic test. Glucocorticoids, immune-modulatory drugs and anticoagulants/anti-platelets have been used empirically in the treatment of inflammatory and vasculopathic causes of NPSLE. However, clinical trial data on these interventions remain sparse.

Although the prognosis of SLE has improved considerably in recent times, NPSLE still remains a major cause of morbidity and mortality. A recent study reported a 19%

mortality rate, with infection and NPSLE attributed as the leading causes of death in SLE patients.¹⁶ Despite the frequent occurrence of brain involvement in SLE, our knowledge of NPSLE syndromes and their association with imaging findings remains speculative. The American College of Rheumatology (ACR) published a consensus for the classification, nomenclature and case definitions for 19 distinct neuropsychiatric syndromes in 1999, with the aim of facilitating research.⁷ The criteria have been subject to debate in several studies, some of which have questioned the low specificity for diffuse syndromes such as headache, cognitive dysfunction and minor psychiatric disorders commonly reported in chronic diseases generally.^{8,17,18}

In a meta-analysis conducted in 2011, headache (12%) was determined as the most prevalent syndrome, followed by mood disorder (7%), seizure disorder (7%), cognitive dysfunction (7%) and cerebrovascular disease (CVD) (5%). PNS syndromes such as autonomic disorder and Guillain-Barré syndrome (GBS) (<0.1%) were rarely reported.⁹ Unterman et al.⁹ reported that Asians (72%), Caucasians (16%) and Hispanics (4%) were the most frequently affected ethnicities.

Brain magnetic resonance imaging (MRI) remains the most commonly used imaging technique to assist in the diagnosis of NPSLE due to its wide availability. Recently, more advanced imaging tools, such as the MRI methods of magnetisation transfer imaging (MTI), diffusion-weighted imaging (DWI) and diffusion tensor imaging (DTI), and methods using radioactive tracers, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), have been increasingly studied.^{15,19} Furthermore, the EULAR task force has recommended the use of advanced imaging in cases of normal MRI findings in patients with NPSLE, providing further rationale to specifically assess MRI. Table 1 lists the different imaging modalities, their descriptions and common findings. SPECT studies have demonstrated a higher sensitivity in patients with diffuse neurological involvement compared with MRI.^{19,26,27} However, the cost and limited availability of SPECT and PET and the need for better standardisation and validation for interpretation of advanced quantitative MRI protocols have prevented their establishment in routine clinical practice thus far.^{15,28,29} For this reason, the focus of our study was conventional MRI.

The aim of this systematic review and meta-analysis was to assess whether the clinical NPSLE syndromes defined by the 1999 ACR criteria are linked to distinct brain MRI abnormality. This is important as any brain MRI

Table 1. Summary of imaging modalities, their descriptions and common findings in NPSLE.

Imaging modality	Findings in NPSLE	Reference
T1-weighted (T1w) MRI	Atrophy	Bertsias et al. ¹⁵
T2-weighted (T2w) MRI	Multifocal white matter hyperintensities (WMHs) in subcortical, periventricular and frontoparietal regions; infarcts	Zardi et al., ¹⁹ Luyendijk et al. ²⁰ and Jennings et al. ²¹
Fluid-attenuated inversion recovery (FLAIR)	Subcortical and periventricular WMH lesions; infarcts	Luyendijk et al., ²⁰ Yaniv et al. ²² and Ercana et al. ²³
Magnetisation transfer imaging (MTI)	Demyelination, ischaemia and oedema major contributors to changes in magnetisation transfer ratio (MTR) and reduced histogram peak heights	Zardi et al., ¹⁹ Ercana et al. ²³ and Bosma et al. ²⁴
Magnetic resonance spectroscopy (MRS)	Reduced NAA levels thought to reflect neuronal injury/death	Zardi et al., ¹⁹ Yaniv et al. ²² and Lim et al. ²⁵
Diffusion-weighted imaging (DWI)	Apparent diffusion coefficient (ADC) of water protons raised due to loss of tissue integrity in grey matter (GM) and white matter (WM)	Zardi et al. ¹⁹ and Yaniv et al. ²²
Diffusion tensor imaging (DTI)	Reduced FA associated with reduction in axonal integrity in WM	Zardi et al., ¹⁹ Yaniv et al. ²² and Govoni et al. ²⁶
Perfusion-weighted imaging (PWI)	Demonstrates areas of hypoperfusion, though with lower sensitivity than SPECT	Govoni et al. ²⁶
Positron emission tomography (PET)	Hypometabolism most commonly detected in parieto-occipital region indicating reduced neuronal density/perfusion	Zardi et al. ¹⁹ and Govoni et al. ²⁶
Single-photon emission computed tomography (SPECT)	Diffuse, focal or multifocal areas of hypoperfusion in frontal, parietal and temporal lobes	Zardi et al., ¹⁹ Govoni et al. ²⁶ and Zhang et al. ²⁷

NPSLE: neuropsychiatric systemic lupus erythematosus; NAA: N-acetylaspartate; MRI: magnetic resonance imaging; FA: fractional anisotropy.

association with specific NPSLE features could potentially aid clinicians in diagnosing NPSLE with more confidence and link individual NPSLE syndromes with structural or pathologic changes such as thrombosis and CVD.

Materials and methods

Search strategy

The electronic databases PubMed, MEDLINE (via Ovid), Embase (via Ovid) and the Cochrane Library were searched from their inception to November 2015. The grey literature and trial registries OpenGrey, WHO International Clinical Trials Registry Platform, Current Controlled Trials and the United States National Institute of Health Trials Registry were also searched from inception to November 2015 for any additional papers omitted from the principle search. The terms used for the MEDLINE search were as follows: systemic lupus erythematosus, neuropsychiatry/neurologic disease, lupus erythematosus, neuropsychiatric systemic lupus erythematosus, lupus vasculitis, CNS, nuclear magnetic resonance imaging, magnetic resonance imaging and MRI.

Study eligibility and identification

Papers were eligible if they provided data on the prevalence of clinical syndromes for NPSLE and presented corresponding brain MRI imaging data to assess the prevalence for individual clinical syndromes. Papers were excluded if

they were reviews, case reports, letters to the editor or studies not published in English or assessing human subjects. Studies were included irrespective of the number of cases of NPSLE evaluated in individual studies due to the relative rarity of NPSLE^{1,2} and to minimise the risk of small sample size publication bias from impacting on the review's analysis. The results of the search strategy were reviewed by two authors (O.A., A.K.). Each title and abstract was assessed against the eligibility criteria. The full texts were obtained for those papers which were thought to be potentially eligible. The same two reviewers assessed the eligibility of each full text, and if they met the criteria, they were included in the review. In our search, we were unable to include comparisons of brain MRI changes in patients without SLE and without neuropsychiatric manifestations, as we were unable to find studies of this kind and we recognise this as a limitation. We were also unable to compare MRI findings between NPSLE versus SLE patients or SLE patients versus healthy controls, as we were unable to find any studies outlining these specified comparisons. Instead, we classified SLE patients based on the outcomes, that is, having normal versus abnormal MRI scans and then compare each group based on individual NPSLE syndrome. There are two issues with this approach. First, the definition of normal MRI scan is more difficult to establish and more subjective. Second, there is no causal relationship or correlation between NPSLE syndrome and MRI finding which can be concluded. Third, there is a chance that some of the NPSLE syndromes may (e.g. anxiety) develop later

despite a normal structural MRI scan. Our results therefore need to be interpreted with these limitations in mind.

Data extraction and appraisal

Data were extracted from each included paper by two reviewers (O.A., A.K.). This was performed independently, with the results verified by each other. Data which were extracted onto our data extraction form included the following: country of study, study design, MRI imaging sequence, number of patients MRI assessed, number of syndromes detected, mean and range of ages of subjects, gender of subjects, duration of NPSLE, age of onset, disease activity, clinical syndromes detected, prevalence of syndromes within the cohort, prevalence of normal and abnormal MRI findings and prevalence of specific MRI findings. The MRI findings extracted included the following: white matter hyperintensities, grey matter hyperintensities, parenchymal defects, cerebral atrophy, large vessel disease, small vessel disease, inflammatory lesions, microbleeds, recent infarct, lacunes, vascular signs, intracranial haemorrhage, focal oedema, diffuse cerebral oedema, punctuate focal lesions, periventricular lesion and microcalcification.

Two reviewers (O.A., A.K.) independently assessed the quality of each included paper using a modified Critical Appraisal Skills Programme (CASP)³⁰ checklist. This was chosen as it is a valid tool which consists of a set of questions designed to evaluate the internal and external validities of clinical studies. The results from each reviewer were evaluated to gain a consensus on the final quality assessment judgement.

Data analysis

An assessment of study heterogeneity was derived through assessment of the data extraction table. Where population, study design, data collection and MRI investigation were considered comparable, a pooled assessment of prevalence of clinical syndromes in NPSLE was made. Similarly, an assessment of pooled prevalence of MRI features for each specific clinical syndrome was made. The risk ratio (RR) was determined of detecting an abnormal MRI result compared to normal MRI for people with NPSLE for each individual clinical syndrome. For each calculation, pooled prevalence was presented as a percentage with 95% confidence intervals (CIs). Similarly, RR was assessed with 95% CIs using a random effects model analysis and statistical heterogeneity using I^2 and χ^2 statistical tests. Sensitivity analyses were conducted, where appropriate assessing outcomes, when there were 100 participants or more to minimise the risk of small study effects from impacting on the outcome.⁵⁴ Small sample size publication bias was assessed using a funnel plot of the most frequently reported NPSLE




Figure 1. Flow chart summarising the results of the search strategy and the process of study inclusion/exclusion.

feature (seizures). All analyses were conducted on RevMan (Review Manager version 5.1; Copenhagen: The Nordic Cochrane Centre (the Cochrane Collaboration, 2011)) and Stata version 12.0 (StataCorp LP, College Station, TX, USA).

Results

Search strategy

A summary of the search results is presented in Figure 1. A total of 821 citations were identified from the search strategy. Of these, 21 were deemed eligible and included in the analysis based on the search criteria.

Study quality assessment

Full assessment of the studies with their total scores is shown in Table 2. The results of the CASP appraisal highlighted several methodological limitations. First, while 90% defined the study population and the recruitment

Table 2. Table showing study characteristics and critical appraisal assessment scores using a modified CASP tool.

Study – author and year	Country	Assessment method	Females, N (%)	Mean age in years ±SD	Mean duration of illness	NPSLE patients/total number of syndromes	Control groups	Total CASP tool score ^a
Sarbu et al. ³¹ (2015)	Spain/UK	1999 ACR	99 (91.7)	40.6 ± 14.2	<6 months	108/123	–	10
Jeong et al. ³² (2015)	South Korea	1999 ACR	103 (87.3)	35.5 ± 13.0	4 months	118/133	–	10
Ariunuma et al. ⁴⁶ (2014)	Japan	1999 ACR	45 (85)	38.9 ± 17.1	47.1 months	53/75	–	9
Toledano et al. ³³ (2014)	Spain	1999 ACR	40 (93)	41.8 ± 12.42	<6 months	43/43	–	9
Toyota et al. ³⁴ (2013)	Japan	1999 ACR	5 (71.4)	30.3	–	7/7	–	6
Luyendijk et al. ²⁰ (2011)	Netherlands	1999 ACR	66 (89)	37.9 ± 13.7	–	74/100	–	8
Katsumata et al. ³⁵ (2010)	Japan	1999 ACR	53 (93)	28	<12 months	57/72	–	6
Sibbitt et al. ³⁶ (2010)	USA	1999 ACR	13 (93)	35 ± 17	–	14/47	–	7
Demirkaya et al. ³⁷ (2008)	Turkey	1997 ACR	12 (86)	17.35 ± 3.24	–	14/27	20 healthy subjects	5
Appenzeller et al. ³⁸ (2006)	Brazil	1999 ACR	18 (90)	32.4 ± 11.8	–	20/48	50 healthy subjects	7
Zhang et al. ²⁷ (2005)	China	1999 ACR	20 (91)	32 ± 17	–	22/22	21 non-CNS SLE subjects	10
Abreu et al. ³⁹ (2005)	Brazil	1982 ACR	13 (100)	41.77 ± 14.9	–	13/13	10 non-CNS SLE subjects	6
Jennings et al. ²¹ (2003)	USA	1999 ACR	81 (95)	40.4	–	85/112	–	5
Bosma et al. ²⁴ (2004)	Netherlands	1999 ACR	24 (100)	35	–	24/26	–	6
Walecki et al. ⁴⁰ (2002)	Poland	1982 ACR	50 (100)	–	–	50/59	–	5
Lim et al. ²⁵ (2000)	South Korea	1982 ACR	16 (94)	33 ± 12	–	17/19	9 non-CNS SLE subjects	7
Sabet et al. ⁴¹ (1998)	USA	1997 ACR	11 (92)	44 ± 7.2	–	12/20	23 healthy and 37 non-CNS SLE subjects	9
Steinlin et al. ⁴² (1995)	Canada	1982 ACR	31 (78)	13.3 ± 2.8	–	40/47	–	5
Baum et al. ⁴³ (1993)	Germany	1982 ACR	19 (90.5)	41.1	–	21/27	–	6
Fields et al. ⁴⁴ (1990)	USA	1982 ACR	5 (100)	31.8	–	5/7	–	6
Sibbitt et al. ⁴⁵ (1989)	USA	1982 ACR	21 (100)	33.9	–	21/37	–	6

CASP: Critical Appraisal Skills Programme; SD: standard deviation; NPSLE: neuropsychiatric systemic lupus erythematosus; ACR: American College of Rheumatology; CNS: central nervous system;

SLE: systemic lupus erythematosus; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; APS: antiphospholipid syndrome; BP: blood pressure.

^aTotal CASP score determined using the questions below (one point for each):

Was there a clear objective for the study to address?

Were participants clearly defined and recruited in an acceptable manner?

Was there a comparison/control group?

Were the criteria for NPSLE clearly defined according to 1999 guidelines?

Were all patients who entered study fully accounted for at its conclusion?

Was there blinding of the neuroradiologist to reduce possible bias?

Was the disease status (symptoms, SLEDAI score etc.) of population described?

Were methods for performing the study described in sufficient detail?

Have authors identified common confounding factors (APS syndrome, BP etc.)?

How precisely were the results presented – p values ± confidence intervals?

Were the results applicable to clinical practice?




Figure 2. Funnel plot of small sample publication bias for the assessment of seizures with NPSLE and abnormal compared versus normal MRI findings.

RR: Risk ratio; SE: standard error

process, only 57% of studies used the 1999 ACR guidelines for NPSLE case definitions, with research published prior to 1999 relying on clinicians for assessment and definitions used. Only 29% enrolled control groups for comparison, with either healthy individuals or SLE participants with no brain involvement serving as controls. Just 24% of the studies described blinding of the neuroradiologist to minimise bias. The quality of the evidence base was further weakened, as 57% of the studies did not mention any confounding factors. A total of 38% of studies carried out a statistical analysis, and 71% described their methods section in sufficient detail.

Characteristics of included studies. In total, 818 individuals (745 females/73 males) with 1064 NPSLE clinical syndromes were included and analysed. The study sample's ages ranged from 13.3⁴² to 44.0 years.⁴¹ The duration from NPSLE diagnosis to MRI was not specified in 16 papers. In three papers, the duration from NPSLE diagnosis to MRI was less than 3 months,^{31,32,33} it was up to 1 year in one study,³⁵ while it was a mean 47.1 months in another study.⁴⁶ Disease activity was defined and reported in eight studies. This ranged from 4.7 Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)³⁸ to 34 SLEDAI³⁶ and 14.2 British Isles Lupus Activity Group (BILAG).⁴⁶

A variety of MRI investigation descriptions were provided. In 10 papers, T1, T2 and fluid-attenuated inversion recovery (FLAIR) were used,^{20,21,31,33–36,46,39,40} four studies

simply stated that MRI was undertaken.^{37,43–45} Imaging was described in individual studies as follows: T1, T2, FLAIR and DWI;³² T1, T2, voxel-based morphometry;³⁸ T1, T2, FLAIR, SPECT;²⁷ T1, T2, FLAIR, MTI;²⁴ T1, T2, magnetic resonance spectroscopy (MRS);²⁵ and MRI, SPECT.⁴²

Five studies were undertaken in the United States,^{21,36,41,44,45} three in Japan,^{34,35,46} two in South Korea,^{25,32} two from the Netherlands^{20,24} and two from Brazil.^{38,39} Single studies were undertaken in Turkey,³⁷ China,²⁷ Poland,⁴⁰ Canada,⁴² Germany⁴³ and Spain,³³ while one study was conducted in both Spain and the United Kingdom.³¹ Nine papers reported retrospective studies, while seven were prospective studies. It was unclear whether the studies were retrospective or prospective in five instances.

Publication bias

Small sample size publication bias was assessed using a funnel plot. As represented in Figure 2, for the measure with the largest data set (seizures), this produced a broadly symmetric funnel plot suggesting low risk of publication bias.

Meta-analysis

Prevalence of clinical syndromes in NPSLE. Pooled prevalence of clinical syndrome in NPSLE was headache, with a prevalence of 23.8% (95% CI: 21.1%–26.9%; N=818). This

Table 3. Pooled prevalence of MRI findings by individual clinical feature for people with NPSLE.

NPSLE syndrome	Top three MRI features – prevalence (95% CI) (N of study)			Normal MRI – prevalence (95% CI)
Headache	Small vessel disease 48.6 (33.0–64.4) (1)	White matter hyperintensity 34.1 (26.6–42.4) (8)	Grey matter hyperintensity 34.1 (26.6–42.4) (8)	48.9 (41.8–56.1) (13)
CVS syndrome	Small vessel disease 79.0 (56.7–91.5) (1)	White matter hyperintensity 66.0 (56.1–74.6) (5)	Parenchymal defects 47.4 (35.5–62.7) (2)	13.2 (8.4–20.1) (10)
Seizures	White matter hyperintensity 61.5 (52.1–70.1) (11)	Cerebral atrophy 56.0 (46.6–64.9) (11)	Small vessel disease 52.6 (31.7–72.7) (1)	37.7 (30.6–45.5) (18)
Cognitive dysfunction	Small vessel disease 78.6 (52.4–92.4) (1)	White matter hyperintensity 72.6 (61.0–81.6) (9)	Cerebral atrophy 45.7 (34.8–57.3) (8)	26.7 (19.1–35.8) (15)
Mood disorders	White matter hyperintensity 50.6 (40.1–61.1) (8)	Cerebral atrophy 34.6 (23.2–48.2) (8)	Parenchymal defects 30.8 (12.7–57.6) (3)	49.4 (38.9–60.0) (16)
Myelopathy	Small vessel disease 75.0 (30.1–95.4) (1)	White matter hyperintensity 57.1 (25.0–84.2) (2)	Inflammatory lesions 50.0 (18.8–81.2) (2)	35.7 (16.3–61.2) (7)
Anxiety	Small vessel disease 33.3 (6.2–79.2) (2)	Cerebral atrophy 33.3 (9.7–70.0) (3)		90.0 (69.9–97.2) (9)
ACS	Small vessel disease 66.7 (20.8–98.4) (1)	White matter hyperintensity 56.9 (44.1–68.8) (5)	Infarct (recent) 38.5 (17.7–64.5) (3)	41.1 (31.7–51.1) (11)
Psychosis	Infarct (recent) 40.0 (11.8–76.9) (3)	White matter hyperintensity 37.5 (22.9–54.8) (7)	Cerebral atrophy 25.6 (14.8–41.1) (7)	57.9 (42.2–72.1) (12)
Aseptic meningitis	Inflammatory lesions 100.0 (34.2–100.0) (2)	Small vessel disease 100.0 (20.7–100.0) (1)	White matter hyperintensity 50.0 (23.7–76.3) (4)	55.0 (34.2–74.2) (8)
Demyelinating syndrome	White matter hyperintensity 100.0 (56.6–100.0) (2)	Small vessel disease 100.0 (20.7–100.0) (1)	Inflammatory lesions 100.0 (20.7–100.0) (1)	10.0 (1.7–40.1) (3)
Cranial neuropathy	White matter hyperintensity 44.4 (24.6–66.3) (3)	Grey matter hyperintensity 15.4 (4.3–42.2) (3)	Infarct (recent) 16.7 (3.0–56.4) (2)	64.0 (44.5–80.0) (6)
Mononeuropathy	Small vessel disease 80.0 (37.6–96.4) (1)	White matter hyperintensity 55.6 (26.7–81.1) (3)	Grey matter hyperintensity 25.0 (4.6–69.9) (2)	40.0 (16.8–68.7) (4)
Polyneuropathy	Grey matter hyperintensity 55.6 (26.7–81.1) (5)	Large vessel disease 50.0 (15.1–85.0) (1)	Small vessel disease 50.0 (15.1–85.0) (1)	22.2 (6.3–54.7) (5)
Plexopathy	White matter hyperintensity 25.0 (4.6–69.9) (3)	Grey matter hyperintensity 0.0 (0.0–65.8) (2)	Parenchymal defects 0.0 (0.0–65.8) (2)	83.3 (43.7–97.0) (4)
Movement disorder	White matter hyperintensity 83.3 (43.7–97.0) (4)	Grey matter hyperintensity 0.0 (0.0–42.5) (3)	Parenchymal defects 0.0 (0.0–42.5) (3)	20.0 (5.7–51.0) (7)
GBS	White matter hyperintensity 50.0 (9.5–90.6) (3)	Grey matter hyperintensity 0.0 (0.0–65.8) (3)	Parenchymal defects 0.0 (0.0–65.8) (3)	50.0 (9.5–90.6) (3)
Myasthenia gravis	White matter hyperintensity 0.0 (0.0–0.0) (2)	Grey matter hyperintensity 0.0 (0.0–0.0) (2)	Parenchymal defects 0.0 (0.0–0.0) (2)	0.0 (0.0–0.0) (2)
Autonomic disorder	Inflammatory lesions 0.00 (0.00–0.00) (1)	Microbleed 0.00 (0.00–0.00) (1)	n/a	100.0 (43.9–100.0) (2)

NPSLE: neuropsychiatric systemic lupus erythematosus; MRI: magnetic resonance imaging; CI: confidence interval; CVS: cerebrovascular syndrome; ACS: acute confusional state; GBS: Guillain-Barré syndrome.

was followed by, in order of frequency, seizures (prevalence: 18.9%; 95% CI: 16.3%–21.7%; N=818), CVD (prevalence: 17.6%; 95% CI: 15.1%–20.4%; N=818) and cognitive dysfunction (prevalence: 15.3%; 95% CI: 13.0%–17.9%; N=818). The least prevalent clinical syndromes were myasthenia gravis (prevalence: 0%; 95% CI: 0.0%–0.01%; N=712), GBS (prevalence: 0.3%; 95% CI: 0.08%–1.1%; N=659), plexopathy (prevalence: 0.9%; 95% CI: 0.4%–2.0%; N=659) and polyneuropathy (prevalence: 1.4%; 95% CI: 0.1%–2.6%; N=659).

RR of an abnormal MRI finding for individual clinical syndromes in NPSLE. A summary of the pooled prevalence of normal and abnormal MRI brain findings for each clinical syndrome with NPSLE is presented in Table 3. There was variable statistical heterogeneity for each of these analyses (Supplementary Table 1). The highest prevalence of normal MRI brain features for individual clinical syndromes in the NPSLE cohort was for anxiety (prevalence: 90%; 95% CI: 69.9%–97.2%; N=20), followed by plexopathy (prevalence 83.3%; 95% CI: 43.7%–97.0%; N=6), cranial




Figure 3. Forest plot of risk ratio of an abnormal compared to normal MRI findings for 19 clinical features of NPSLE.

neuropathy (prevalence: 64.0; 95% CI: 44.5%–80.0%; N=25) and aseptic meningitis (prevalence: 55.0%; 95% CI: 34.2%–74.2%; N=20). When solely assessing analyses of over 100 subjects, the highest prevalence of normal MRI brain features was for headache (prevalence: 48.9%; 95% CI: 41.8%–56.1%; N=184), seizures (prevalence: 37.7%; 95% CI: 30.6%–45.5%; N=159) and cognitive dysfunction (prevalence: 26.7%; 95% CI: 19.1%–35.8%; N=105). Seven clinical syndromes demonstrated statistically significant association when assessed with RR. CVD, seizures, cognitive dysfunction, acute confusional state (ACS), demyelinating syndrome and movement disorders all demonstrated a greater risk of demonstrating abnormal MRI brain findings in people with NPSLE. Only anxiety was shown to have a lower risk of an abnormal MRI brain finding in NPSLE (RR: 9.00; 95% CI: 2.40–33.79; N=20) (Figure 3).

Prevalence of MRI features for individual clinical syndromes in NPSLE. The prevalence data for each individual abnormal MRI brain feature and the clinical syndrome are presented in Table 3. The most prevalent MRI features were white matter hyperintensities (WMHs) (34.1%), grey matter hyperintensities (GMHs) (22.9%), parenchymal defects (6.5%), cerebral atrophy (16.9%) and small vessel disease (48.6%). On assessment of the 10 distinct brain MRI changes that we evaluated, CVD showed positive MRI findings in all categories, the most prevalent of which were white matter hyperintensity (66%), small vessel disease (79.0%), grey matter hyperintensity (44.8%) and parenchymal defects (47.4%). Headache demonstrated positive MRI features in 6 of the 10 categories assessed, with the most frequent findings being small vessel disease (48.6%) and white matter hyperintensity (34.1%). All the clinical syndromes were assessed for nine MRI abnormalities;

in several, MRI findings were not observed, including myasthenia gravis features (100% MRI scans did not show abnormalities), plexopathy (88.9%), movement disorder (88.9%), GBS (88.9%), myelopathy (44.4% MRI changes not seen), anxiety (66.7%) and mood disorders (33.3%).

Discussion

Despite the presence of NPSLE syndromes with varying disease severity, a normal imaging outcome on conventional MRI was frequently observed in our study. The most common NPSLE syndromes in patients undergoing MRI evaluation in our selected studies were headache (23.8%), seizures (18.9%), CVD (17.6%), cognitive dysfunction (15.3%), ACS (13.8%) and mood disorders (11.1%). CNS manifestations were more frequent than PNS ones (91.3% vs 8.7%).

The most significant findings from our meta-analysis were the observation of normal brain MRI in a variety of clinical syndromes, including psychiatric syndromes such as anxiety (RR: 9.00) and PNS features such as autonomic disorder (RR: 7.00) and plexopathy (RR: 5.00). Associations between abnormal brain MRI and clinical NPSLE syndromes were observed in a broad range of clinical features including CVD (RR: 0.15), demyelination (RR: 0.11) and seizures (RR: 0.61).

Brain MRI in NPSLE is often conducted as part of the clinical workup, especially before performing a lumbar puncture. We found a low detection rate of distinct clinical NPSLE features correlating with specific brain MRI changes. Nevertheless, it is important to take into account that patients with objective syndromes such as seizures and CVD present with overt symptoms may undergo MRI scans sooner, while milder manifestations of subjective syndromes like cognitive dysfunction, mood or anxiety

disorder may not be referred for MRI investigation until reaching a clinically severe stage. This reduces the reliability of the prevalence values with this possibility leading to an under- or over-estimation of some features. Interestingly, the EULAR task force recommended MRI investigation more urgently in selected syndromes.¹⁵ Notably, our meta-analysis included studies which did not investigate all 19 NPSLE syndromes. For example, Toyota et al.³⁴ included only seizure patients in NPSLE. This may have therefore led to selection bias when estimating prevalence values.

The 21 included studies reported inconsistent details of MRI lesions in terms of their size, number and locations. The radiographic terms used to describe and list these into specific groups often differed, as no standard guidelines were adhered to. Hence, the resulting wide heterogeneity of lesion descriptions in the studies made cross-comparisons difficult. It was therefore decided to group them into themes of the most recurring terms used, which in our selected studies were WMH, GMH and atrophy. The 'vascular lesion' group consisted of descriptions, which could be confidently assigned into this particular category which included 'microbleeds', 'infarcts', 'lacunar lesions' and 'intracranial haemorrhage'. Any terms recorded, where a degree of uncertainty existed over which category they would fit into best, were categorised as 'other'. We found that WMHs were consistently the most frequently reported abnormality (33.1%–53.3%) among the eight most prevalent syndromes, followed by vascular lesions (6.7%–31.7%), although a considerable overlap between the two is likely. Atrophy was also a common feature (6.7%–35.7%), while GMHs were less frequent (2.8%–14.4%).

The precise role of distinct MRI lesions in the pathophysiology of NPSLE remains uncertain. Focal WMH lesions have been linked to various non-specific changes such as necrosis, reduced neuronal density, inflammatory infiltrates and demyelination. An underlying acute infarct has been suggested in areas where reduced diffusion was observed secondary to cytotoxic oedema, while bilateral WMHs are thought to be a sign of chronic hypoperfusion.²⁰ Common sites of WMH lesions are in the frontoparietal region, periventricular and subcortical white matter, and their presence has been recorded in both active and inactive NPSLE.^{29,47–49} Although evidence still persists that WMHs are not specific to NPSLE, as it was shown in SLE without overt neuropsychiatric involvement, they were found to be higher in quantity and total volume in active and past NPSLE when compared with non-NPSLE patient groups.⁵⁰ Specifically, a correlation between cognitive dysfunction, cerebrovascular syndrome and WMHs has been shown in previous studies.^{31,47}

Atrophy is another non-specific radiographic finding in NPSLE patients, and many factors have been associated to contribute towards it, including disease duration, corticosteroid use, advancing age and presence of antiphospholipid syndrome (APS).⁴⁷ However, a recent study found that

participants with NPSLE had significantly pronounced atrophy compared to SLE with no brain involvement and healthy controls, after adjusting for age.⁵¹ Histopathologic correlations for atrophy vary, having been observed in patients with diffuse and focal brain injury.^{36,52,53} Atrophy has been found to be significantly associated with cognitive dysfunction, seizure disorder and CVD in another study.⁴⁷

MRI results in other diffuse syndromes such as ACS, psychosis and anxiety disorder were investigated by Arinuma et al.⁴⁶ and found to be normal in 52.8% of the cases. Another study pointed out that the rate of abnormal lesions detected on conventional MRI in diffuse syndromes was not significantly different from SLE patients with no neuropsychiatric involvement.⁵⁰ They concluded that while MRI remains sensitive for focal lesions, a combined approach of morphological and functional imaging, such as SPECT, would be more helpful in excluding brain abnormalities in diffuse syndromes with normal MRI. Our findings suggest that although small in sample size, patients with SLE with anxiety or peripheral nerve symptoms are significantly and mostly likely to have normal structural MRI scans. The findings from our study are preliminary, and more MRI research needs to be done on SLE patients with anxiety, autonomic disorder, plexopathy and polyneuropathy.

Our study presents with a small number of important limitations. First, only a small number of papers reported disease activity measure or the time of disease onset to MRI evaluation. Similarly, details on treatment were rarely presented which could have introduced a bias since patients may have been given effective treatment before undergoing MRI scanning. Another source of bias could have arisen from the patient selection in the individual studies. As not all NPSLE patients are referred for MRI investigation, it is likely that the patients in our analysis may be different in terms of disease severity from patients where MRI referral was not warranted. There were also limited data provided on ethnicity of participants. Other potential sources of bias to limit generalisability included the lack of blinding of the neuroradiologist reporting the MRI images. Only 26% of the studies explicitly stated that appropriate measures were taken to ensure minimal bias in this regard. Variations between MRI scanner resolutions across the studies may have led to inconsistencies in evaluating imaging findings. This is difficult to prevent in retrospective designs, which in our case consisted of studies published between 1989 and 2014. Additionally, the introduction of FLAIR imaging techniques, which were used only in studies from 2002 onwards in our study, could have added to a difference in the reporting of MRI findings. A potential pitfall in interpreting MRI outcomes includes the occurrence of overlapping syndromes for patients presenting with more than one NPSLE syndrome. In these cases, it is difficult, if not impossible, to reliably ascribe MRI outcomes to a particular syndrome with certainty. In our study, it was not

possible to combine quantitative neuroimaging data due to the broad nature of the studies involved. Although the conventional way is voxel or co-ordinate-based meta-analyses of neuroimaging data which will identify neuroanatomical areas affected by NPSLE, it was not possible to do such analyses from the studies we identified. We therefore recognise that assigning an MRI as either 'normal' or 'abnormal' has its limitations but was necessary in our study due to the wide variability in the data extracted. Finally, our review did not exclude studies and analyses based on the number of cases of NPSLE evaluated in individual studies. This minimised the risk of small sample size publication bias from impacting on the review's findings. However, the consequence of this was that for a number of features, such as autonomic disorders, demyelinating syndrome and GBS, there were very few events included in the analysis, thereby presenting under-powered results. As the evidence base develops, it is anticipated that further analyses will be undertaken to better understand NPSLE.

Conclusion

The results of this article suggest that – despite being the current imaging modality of choice in NPSLE – MRI should not be used in isolation to make a diagnosis due to its inability in some circumstances to differentiate changes from non-NPSLE presentations. In the future, the development of morphological and metabolic or functional imaging tools could be more useful in early monitoring of cerebral involvement, thereby allowing earlier effective treatment and improved survival for this population.

Acknowledgements

The authors would like to thank Judith Scammell for assistance with literature search.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship and/or publication of this article.

References

1. Tsokos GC. Systemic lupus erythematosus. *N Engl J Med* 2011; 365: 2110–2121.
2. Bertias G and Ricard Cervera R. Systemic lupus erythematosus: pathogenesis and clinical features. In: *EULAR on-line course on rheumatic diseases*, 2012, pp. 476–505, http://www.eular.org/myuploaddata/files/sample%20chapter20_mod%2017.pdf
3. Shipley M, Rahman A, O'Gradaigh D, et al. Rheumatology and bone disease. In: Kumar P and Clark M (eds) *Clinical medicine*. 7th ed. Edinburgh: Saunders Elsevier, 2009, pp. 541–544.
4. Petri M. Epidemiology of systemic lupus erythematosus. *Best Pract Res Clin Rheumatol* 2002; 16(5): 847–858.
5. Cervera R and Espinosa G. Systemic lupus erythematosus: pathogenesis, clinical manifestations and diagnosis. In: *EULAR online course rheumatic diseases*, 2009, pp. 1–31, http://www.eular-onlinecourse.org/sample_chapter/module17.pdf
6. Hanly JG. Neuropsychiatric lupus. *Rheum Dis Clin North Am* 2005; 31(2): 273–298.
7. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. *Arthritis Rheum* 1999; 42(4): 599–608.
8. Sciascia S, Bertolaccini ML, Baldovino S, et al. Central nervous system involvement in systemic lupus erythematosus: overview on classification criteria. *Autoimmun Rev* 2013; 12(3): 426–429.
9. Unterman A, Nolte JES, Boaz M, et al. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. *Semin Arthritis Rheum* 2011; 41(1): 1–11.
10. Jeltsch-David H and Muller S. Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. *Nat Rev Neurol* 2014; 10(10): 579–596.
11. Popescu A and Kao A H. Neuropsychiatric systemic lupus erythematosus. *Curr Neuropharmacol* 2011; 9(3): 449–457.
12. Pradhan V, Patwardhan M, Rajadhyaksha A, et al. Neuropsychiatric manifestations and associated autoantibodies in systemic lupus erythematosus patients from Western India. *Rheumatol Int* 2015; 35: 541–545.
13. Zandman-Goddard G, Chapman J and Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. *Semin Arthritis Rheum* 2007; 36(5): 297–315.
14. Karassa FB, Ioannidis JP, Touloumi G, et al. Risk factors for central nervous system involvement in systemic lupus erythematosus. *QJM* 2000; 93(3): 169–174.
15. Bertias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. *Ann Rheum Dis* 2010; 69(12): 2074–2082.
16. Zirkzee E, Huizinga T, Bollen E, et al. Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). *Lupus* 2014; 23(1): 31–38.
17. Nived O, Sturfelt G, Liang MH, et al. The ACR nomenclature for CNS lupus revisited. *Lupus* 2003; 12(12): 872–876.
18. Ainiala H, Hietaharju A, Loukkola J, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. *Arthritis Rheum* 2001; 45: 419–423.
19. Zardi EM, Taccone A, Marigliano B, et al. Neuropsychiatric systemic lupus erythematosus: tools for the diagnosis. *Autoimmun Rev* 2014; 13(8): 831–839.
20. Luyendijk J, Steens S, Ouwendijk W, et al. Neuropsychiatric systemic lupus erythematosus: lessons learned from magnetic resonance imaging. *Arthritis Rheum* 2011; 63(3): 722–732.
21. Jennings JE, Sundgren PC, Attwood J, et al. Value of MRI of the brain in patients with systemic lupus erythematosus and neurological disturbance. *Neuroradiology* 2004; 46: 15–21.

22. Yaniv G, Twig G, Mozes O, et al. Central nervous system involvement in systemic lupus erythematosus: an imaging challenge. *Isr Med Assoc J* 2013; 15: 450–454.
23. Ercana E, Ingoa C, Tritanonb O, et al. A multimodal MRI approach to identify and characterize microstructural brain changes in neuropsychiatric systemic lupus erythematosus. *Neuroimage Clin* 2015; 8: 337–344.
24. Bosma GPT, Steens SCA, Petropoulos H, et al. Multisequence magnetic resonance imaging study of neuropsychiatric systemic lupus erythematosus. *Arthritis Rheum* 2004; 50(10): 3195–3202.
25. Lim MK, Suh CH, Kim HJ, et al. Systemic lupus erythematosus: brain MR imaging and single-voxel hydrogen 1 MR spectroscopy. *Radiology* 2000; 217: 43–49.
26. Govoni M, Castellino G, Padovan M, et al. Recent advances and future perspective in neuroimaging in neuropsychiatric systemic lupus erythematosus. *Lupus* 2004; 13: 149–158.
27. Zhang X, Zhu Z, Zhang F, et al. Diagnostic value of single-photon-emission computed tomography in severe central nervous system involvement of systemic lupus erythematosus: a case-control study. *Arthritis Rheum* 2005; 53(6): 845–849.
28. Joseph FG and Scolding NJ. Neurolupus. *Pract Neurol* 2010; 10: 4–15.
29. Appenzeller S, Pike GB and Clarke AE. Magnetic resonance imaging in the evaluation of central nervous system manifestations in systemic lupus erythematosus. *Clin Rev Allergy Immunol* 2008; 34(3): 361–366.
30. Critical Appraisal Skills Programme (CASP). *CASP checklists*, Oxford, 2014, <http://www.casp-uk.net/>
31. Sarbu N, Alobeidi F, Toledano P, et al. Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. *Autoimmun Rev* 2015; 14(2): 153–159.
32. Jeong HW, Her M, Bae JS, et al. Brain MRI in neuropsychiatric lupus: associations with the 1999 ACR case definitions. *Rheumatol Int* 2015; 35: 861–869.
33. Toledano P, Sarbu N, Espinosa G, et al. Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features. *Autoimmun Rev* 2013; 12(12): 1166–1170.
34. Toyota T, Akamatsu N, Tanaka A, et al. Mesial temporal lobe epilepsy as a neuropsychiatric syndrome of systemic lupus erythematosus. *Epilepsia* 2013; 54(3): e33–e36.
35. Katsumata Y, Harigai M, Kawaguchi Y, et al. Diagnostic reliability of magnetic resonance imaging for central nervous system syndromes in systemic lupus erythematosus: a prospective cohort study. *BMC Musculoskelet Disord* 2010; 11: 13.
36. Sibbitt WL, Brooks WM, Kornfeld M, et al. Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus. *Semin Arthritis Rheum* 2010; 40(1): 32–52.
37. Demirkaya E, Bilginer Y, Aktay-Ayaz N, et al. Neuropsychiatric involvement in juvenile systemic lupus erythematosus. *Turk J Pediatr* 2008; 50: 126–131.
38. Appenzeller S, Amorim BJ, Ramos CD, et al. Voxel-based morphometry of brain SPECT can detect the presence of active central nervous system involvement in systemic lupus erythematosus. *Rheumatology* 2007; 46(3): 467–472.
39. Abreu MR, Jakosky A, Folgerini M, et al. Neuropsychiatric systemic lupus erythematosus: correlation of brain MR imaging, CT, and SPECT. *Clin Imaging* 2005; 29: 215–221.
40. Walecki J, Sierakowski S, Lewszuk A, et al. MR in neurological syndromes of connective tissue diseases. *Med Sci Monit* 2002; 8(6): MT105–MT111.
41. Sabet A, Sibbitt WL, Stidley CA, et al. Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. *Stroke* 1998; 29: 2254–2260.
42. Steinlin MI, Blaser SI, Gilday DL, et al. Neurologic manifestations of pediatric systemic lupus erythematosus. *Pediatr Neurol* 1995; 13(95): 191–197.
43. Baum KA, Hopf U, Nehrig C, et al. Systemic lupus erythematosus: neuropsychiatric signs and symptoms related to cerebral MRI findings. *Clin Neurol Neurosurg* 1993; 95(1): 29–34.
44. Fields RA, Sibbitt WL, Toubbeh H, et al. Neuropsychiatric lupus erythematosus, cerebral infarctions, and anticardiolipin antibodies. *Ann Rheum Dis* 1990; 49: 114–117.
45. Sibbitt WL, Sibbitt RR, Griffey RH, et al. Magnetic resonance and computed tomographic imaging in the evaluation of acute neuropsychiatric disease in systemic lupus erythematosus. *Ann Rheum Dis* 1989; 48: 1014–1022.
46. Arinuma Y, Kikuchi H, Wada T, et al. Brain MRI in patients with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. *Lupus Sci Med* 2014; 1: e000050.
47. Ainiala H, Dastidar P, Loukkola J, et al. Cerebral MRI abnormalities and their association with neuropsychiatric manifestations in SLE: a population-based study. *Scand J Rheumatol* 2005; 34: 376–382.
48. Brey RL. Neuropsychiatric lupus: clinical and imaging aspects. *Bull NYU Hosp Jt Dis* 2007; 65: 194–199.
49. Katsiari CG, Vikelis M, Paraskevopoulou ES, et al. Headache in systemic lupus erythematosus vs multiple sclerosis: a prospective comparative study. *Headache* 2011; 51: 1398–1407.
50. Castellino G, Padovan M, Bortoluzzi A, et al. Single photon emission computed tomography and magnetic resonance imaging evaluation in SLE patients with and without neuropsychiatric involvement. *Rheumatology* 2008; 47: 319–323.
51. Jung RE, Segall JM, Grazioplene RG, et al. Cortical thickness and subcortical gray matter reductions in neuropsychiatric systemic lupus erythematosus. *PLoS ONE* 2010; 5(3): e9302.
52. Zimny A, Szmyrka-Kaczmarek M, Szewczyk P, et al. In vivo evaluation of brain damage in the course of systemic lupus erythematosus using magnetic resonance spectroscopy, perfusion-weighted and diffusion-tensor imaging. *Lupus* 2014; 23: 10–19.
53. Scolding NJ and Joseph FG. The neuropathology and pathogenesis of systemic lupus erythematosus. *Neuropathol Appl Neurobiol* 2002; 28: 173–189.
54. Nüesch E, Trelle S, Reichenbach S, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. *BMJ* 2010; 341: c3515.